Figure 3. Exosome-mediated delivery of CRISPR/Cas9 inhibits tumor growth in a syngeneic allograft model of pancreatic cancer.
KPC689 cells (106) were implanted subcutaneously into the flank of B6-albino mice. The mice were divided into five treatment groups (n = 8 mice in each group) and injected i.v. and intratumorally (I.T.) every other day for 2 wk. (A) Tumor volume measurements at end point. (B) Body weight of mice at end point. (C) Tumor weight at experimental end point. (D) Tumor burden (tumor weight/body weight) at end point. (E) Expression mRNA levels of intratumoral cas9 assessed by quantitative PCR (normalized to 18s). Statistical analysis was performed based on based on ΔCT values. n = 5 mice per group. (F) Intratumoral synthetic guide RNA assessed by QIAxcel capillary gel electrophoresis. All measurements are expressed as mean ± SEM. Kruskall–Wallis with Dunn’s multiple comparison test performed. *P < 0.05.
Source data are available for this figure.
